Patients with heart disease or cardiovascular disease progressed acute disease progression with COVID-19
Synthetic lung organoids provide a high throughput platform to identify new cellular targets of SARS-CoV-2
Stopping RAS inhibitors is associated with a risk of adverse outcomes in patients with chronic kidney disease